Paper42889196PubMed
Survival and prognostic factors analysis of carbon ion radiotherapy for limited-stage small cell lung cancer.
Liang X and 9 others. Front Oncol, 2026.
Cite this record
ConductScience Library. Survival and prognostic factors analysis of carbon ion radiotherapy for limited-stage small cell lung cancer. Papers, record 42889196. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42889196
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Survival and prognostic factors analysis of carbon ion radiotherapy for limited-stage small cell lung cancer.
- Journal
- Front Oncol
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-19
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28642008 | Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28642008 | PubMed |
| 2 | 40163214 | Small Cell Lung Cancer: A Review. | JAMA | 2025 | https://conductscience.org/library/papers/40163214 | PubMed |
| 3 | 35756194 | Value of carbon-ion radiotherapy for early stage non-small cell lung cancer. | Clin Transl Radiat Oncol | 2022 | https://conductscience.org/library/papers/35756194 | PubMed |
| 4 | 36813178 | Metrics of dose to highly ventilated lung are predictive of radiation-induced pneumonitis in lung cancer patients. | Radiother Oncol | 2023 | https://conductscience.org/library/papers/36813178 | PubMed |
| 5 | 40976711 | Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial. | Cancer Sci | 2025 | https://conductscience.org/library/papers/40976711 | PubMed |
| 6 | 38436509 | The sensitivity of radiobiological models in carbon ion radiotherapy (CIRT) and its consequences on the clinical treatment plan: Differences between LEM and MKM models. | J Appl Clin Med Phys | 2024 | https://conductscience.org/library/papers/38436509 | PubMed |
| 7 | 40337202 | Progress in radiotherapy for small-cell lung cancer. | Precis Radiat Oncol | 2023 | https://conductscience.org/library/papers/40337202 | PubMed |
| 8 | 38770179 | Review of Recent Improvements in Carbon Ion Radiation Therapy in the Treatment of Glioblastoma. | Adv Radiat Oncol | 2024 | https://conductscience.org/library/papers/38770179 | PubMed |
| 9 | 37840518 | Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission. | Tumour Biol | 2024 | https://conductscience.org/library/papers/37840518 | PubMed |
| 10 | 28678434 | Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer. | Cancer | 2017 | https://conductscience.org/library/papers/28678434 | PubMed |
| 11 | 35466552 | Comparative effectiveness and toxicity of radiotherapy regimens in limited stage small cell lung cancer: A network meta-analysis. | Cancer Med | 2022 | https://conductscience.org/library/papers/35466552 | PubMed |
| 12 | 40680613 | Comparison of LEM and MKM based RBE-weighted doses from microdosimetric measurements with silicon 3D microdosimeter. | Phys Med | 2025 | https://conductscience.org/library/papers/40680613 | PubMed |
| 13 | 28598362 | Carbon Ion Radiotherapy: A Review of Clinical Experiences and Preclinical Research, with an Emphasis on DNA Damage/Repair. | Cancers (Basel) | 2017 | https://conductscience.org/library/papers/28598362 | PubMed |
| 14 | 35692124 | Carbon-ion radiotherapy for urological cancers. | Int J Urol | 2022 | https://conductscience.org/library/papers/35692124 | PubMed |
| 15 | 37418123 | SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022). | Clin Transl Oncol | 2023 | https://conductscience.org/library/papers/37418123 | PubMed |
| 16 | 40313077 | Real-World Analysis of Treatment Patterns in Limited-Stage Small Cell Lung Cancer: Implications for Clinical Practice. | Thorac Cancer | 2025 | https://conductscience.org/library/papers/40313077 | PubMed |
| 17 | 40597875 | Immunotherapy concurrently administered with chemoradiotherapy in limited-stage small-cell lung cancer. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40597875 | PubMed |
| 18 | 38802836 | Optimizing double-layered convolutional neural networks for efficient lung cancer classification through hyperparameter optimization and advanced image pre-processing techniques. | BMC Med Inform Decis Mak | 2024 | https://conductscience.org/library/papers/38802836 | PubMed |
| 19 | 39146944 | High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial. | Lancet Respir Med | 2024 | https://conductscience.org/library/papers/39146944 | PubMed |
| 20 | 40785643 | A Comprehensive Study on Clinical Outcomes and Safety of Neoadjuvant Immunotherapy Combined With Chemotherapy in Limited-Stage Small Cell Lung Cancer. | Thorac Cancer | 2025 | https://conductscience.org/library/papers/40785643 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42889196
GET https://conductscience.org/api/papers/v1/42889196/references?page=2